Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...

Sanofi would maintain a 48% stake in Opella. Jones Day is advising Sanofi on the capital markets aspects of the separation of Opella and on real estate matters and vendor due diligence for the ...

Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...

The sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at 16 billion euros ($17.4 billion), Sanofi said. "Sanofi and CD&R announce ...

Per the terms of the deal, Sanofi will remain a significant shareholder of Opella. In addition, the French investment bank, Bpifrance, is likely to hold a 2% stake and become a minority ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...

According to Sanofi, the sale of a controlling 50 percent stake in Opella to Clayton Dubilier & Rice (CD&R) has valued the maker of France's leading painkiller, Doliprane, at €16 billion. " ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...